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Abstract
OBJECTIVES: Acute kidney injury (AKI) is a serious complication of cardiac surgery. Statins may prevent post-surgical AKI, yet methodo-
logical concerns about existing studies raise questions about the magnitude of a protective effect. We sought to determine the effect of
initiating a statin prior to elective cardiac surgery on post-surgical AKI in a regional Danish surgical cohort.
METHODS: We identified adults who underwent cardiac surgery during 2006–11 using the Western Denmark Heart Registry. Presurgical
medication use, pre- and post-surgical serum creatinine (sCr) measures, and other patient characteristics were obtained from Danish
population-based registries. Post-surgical AKI was assessed using sCr measures within 5 days of surgery. The adjusted risk ratio (RR) of AKI
and 95% confidence interval (CI) were estimated for patients who initiated a statin within 100 days prior to surgery compared with patients
without prior statin use; long-term statin users were excluded to reduce healthy-user bias. Subanalyses were stratified by surgery type: cor-
onary artery bypass grafting (CABG) and non-CABG surgeries.
RESULTS: We identified 1929 CABG and 1775 non-CABG patients. AKI occurred in 25% of CABG and 28% of non-CABG surgeries, and in
29% of the non-users and 21% of the statin initiators. Half of CABG patients and 9% of non-CABG patients initiated a statin prior to surgery.
The adjusted RRs for the effect of statin initiation on AKI were as follows: all surgeries combined, RR = 0.86 (95% CI: 0.74, 0.98); CABG,
RR = 0.88 (0.74, 1.05); non-CABG RR = 0.87 (0.68, 1.11).
CONCLUSIONS: Presurgical statin initiation is associated with a reduction in AKI risk after cardiac surgery.
Keywords: Surgical outcomes • Perioperative management • Acute renal failure • Acute kidney injury
INTRODUCTION
Post-surgical acute kidney injury (AKI) increases the complexity
of surgical hospitalizations [1] and increases long-term risks of
chronic kidney disease (CKD), cardiovascular disease (CVD) and
mortality [2, 3]. With limited interventions available to reduce
the incidence of postoperative AKI, interest has increased in the
potentially renoprotective effects of statins.
Some clinical studies have demonstrated reduced post-surgical
AKI in statin users [4], but the data are mixed, and others have
not shown a protective effect [5]. Methodological limitations of
non-randomized studies and under-powering of randomized
trials have resulted in continuing uncertainty about the magnitude
and reality of the effect.
Cardiac surgery patients’ indications for statin use can vary widely,
and prior studies have included heterogeneous patient groups: cor-
onary artery bypass graft (CABG) patients with advanced coronary
artery disease (CAD); and non-CABG cardiac surgery (e.g. aortic
resections, valve replacement etc.) patients without CAD but at
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high risk for surgically induced AKI due to the invasiveness of the
surgery and subsequent longer renal ischaemia time. With different
underlying relationships to statins, the effect should be investigated
separately in different surgical populations.
We estimated the effect of presurgical statin initiation in Danish
surgical patients with rich clinical information and comprehensive
medication use histories. We sought to determine whether surgi-
cal patients not previously on statins would benefit from initiating
one prior to surgery.
METHODS
We conducted a historical new-user cohort study of cardiac
surgery patients in Western Denmark.
Data sources
We identified cardiac surgeries occurring between 1 April 2006 and
31 December 2011 in two surgical centres in Aarhus and Aalborg,
Denmark using the Western Denmark Heart Registry (WDHR), which
records information about cardiothoracic surgeries performed in
western Denmark [6]. We utilized WDHR patients in Denmark’s
Northern and Central Regions; the source population includes 1.8
million individuals accessing Denmark’s uniform healthcare system,
which includes partial reimbursement of dispensed medications.
Unique patient identifiers allow for linking across registries.
WDHR patients were linked to: the clinical laboratory informa-
tion system (LABKA) research database [7], which contains longitu-
dinal serum creatinine (sCr) measurements; the National Database
of Reimbursed Prescriptions, which records reimbursed dispensed
medications from community pharmacies [8] and the Danish
National Patient Register, which contains clinical information
about all patients in hospitals, outpatient specialist clinics and
emergency rooms in Denmark since 1995 [9] to collect comorbid-
ities and prior cardio- and cerebrovascular events.
Participants
We identified 15+ year old patients undergoing cardiac surgery, not
including heart transplantation. We restricted our cohort study to
planned, elective procedures—meaning the time from referral to
surgery was equal to or greater than 2 days—to exclude emergency
surgeries, which may systematically have worse outcomes and less
opportunity for presurgical pharmaceutical intervention. We excluded
those with prior heart or lung transplants or dialysis, and those
without recent presurgical (within 10 days) or post-surgical (within 5
days) sCr measurements to ensure accurate AKI assessments.
We categorized surgeries as CABG or non-CABG (e.g. valve re-
placement, aortic resection, atrial septum repair, other). Due to
differences in aetiology, treatment, patient and surgical character-
istics and potential for confounding, we also analysed CABG and
non-CABG procedures separately. If a patient had a CABG and
non-CABG procedure in the same surgery, it was analysed with
the CABG group due to the stronger probability of statin use
resulting from the existing CAD.
Exposure assessment
We collected pharmacy records for 2 years before surgery. If a
statin was dispensed prior to 100 days before surgery, the patient
was considered a prevalent, long-term user and was excluded to
avoid comparing cardiac surgeries in patients with controlled car-
diovascular disease with those with uncontrolled disease, which
may systematically have worse outcomes. Patients given a new
statin in the 100 days prior to hospital admission for surgery were
considered new initiators. We employed the 100-day initiation
window to avoid bias due to the healthy-user effect [10], restrict
the cohort study to those with short periods of presurgical use
and identify those with at least one active course of statin treat-
ment at the time of hospitalization (100 days is the maximum day
supply available). Those without any statin dispensed in the 2
years prior to surgery were considered non-users (see Fig. 1).
Outcome assessment
The most recent sCr measurement within 10 days prior to surgery
was considered the baseline. Post-surgical AKI was assessed
by comparing sCr measures within 5 days of surgery to baseline
and was classified according to Kidney Disease: Improving Global
Outcomes (KDIGO) change in sCr criteria [11]. If a patient required
post-surgical dialysis, they qualified as AKI stage 3.
Covariate assessment
Surgical and patient characteristics were collected by the WDHR at
the time of surgery and included the European System for Cardiac
Operative Risk Evaluation I (EuroSCORE I) [12], a composite risk
score of surgical mortality, which we categorized into low, medium
and high risk. The baseline estimated glomerular filtration rate
(eGFR) was calculated from the baseline sCr measurement using
the Chronic Kidney Disease Epidemiology Collaboration equation
[13] and was categorized into CKD stages using National Kidney
Foundation Kidney Disease Outcomes Quality Initiative guidelines
[14]. We ascertained information on prior cardiovascular and cere-
brovascular events, and the Charlson Comorbidity Index from the
National Patient Register. Our diabetes mellitus definition included
treatment information from the WDHR and diagnoses from the
National Patient Register. Dispensing of other classes of cardiovas-
cular medications and non-steroidal anti-inflammatory drugs
during the 100 days prior to surgery was captured from the
National Database of Reimbursed Prescriptions.
Statistical analysis
Adjusted risk ratios (RRs) and 95% confidence intervals (CIs) were
estimated using multivariable Poisson models with robust variance
Figure 1: Study design schematic of presurgical statin initiators versus non-users
for the risk of post-surgical AKI. AKI: acute kidney injury.
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estimators [15] comparing patients who newly initiated a statin
within 100 days prior to surgery with patients without prior statin
use. Models were adjusted for preselected confounding variables.
Composite scores such as the EuroSCORE and the Charlson
Comorbidity Index were used for descriptive analyses but were not
included as adjustment variables because the relevant components
were included as individual covariates.
As the statin effect and confounding may vary in different surgi-
cal populations, we also performed stratified subgroup analyses
by surgery type—CABG and non-CABG.
Propensity score models
Propensity scores (PSs) were estimated using multivariable logistic
regression models with the preselected potential confounders as
predictors. PS distributions were plotted by treatment group to
observe the comparability of the statin initiators and non-users [16].
Using the PS, we created a standardized mortality ratio-weighted
population where non-users were weighted to have a similar PS dis-
tribution to and balanced covariates with the statin initiators [16].
The RR for statin initiation on AKI was re-estimated in the resulting
weighted population, resulting in the average treatment effect
in the treated. We bootstrapped 300 iterations of the model to
estimate CIs [17].
Sensitivity analysis
To determine the sensitivity of the results to model specifications,
we repeated the analyses with more complex covariate modelling
decisions: continuous variables were modelled as cubic splines
with nodes at: age (40, 60, 80 years); body mass index (BMI)
(25, 30 kg/m2) and eGFR (60, 90 ml/min/1.73 m2).
To determine whether aggregation of the surgeries obscured
the treatment effect, we also estimated the effect of statin initi-
ation in smaller, more homogeneous surgical subtypes.
We also estimated the treatment effect in various clinical sub-
groups: males/females; in those with and without pre-existing renal
impairment [glomerular filtration rate (GFR) <60]; and in primary
versus secondary cardiovascular prevention (those with and without
prior myocardial infarction).
We also investigated the treatment effect separately in the two
different surgical centres.
Study logistics
This study was approved by the Danish Data Protection Agency
(Central Denmark Region record number: 1-16-02-448). Signed
consent was not required from participants. Analyses were per-
formed with SAS 9.2 (SAS Institute, Cary, NC, USA).
RESULTS
We identified 3768 patients who were either new statin initiators
or non-users at the time of surgery. Sixty-four surgeries could not
be accurately classified, leaving 1929 (53%) CABG patients and
1775 (47%) non-CABG patients. Distributions of selected patient
characteristics by surgery type and statin use are given in Table 1
(see Supplementary Table 1 for full characteristics). CABG patients
were older and were more likely to be smokers, be overweight,
have diabetes and cardiovascular comorbidities and use other
medications (except for diuretics, which were more common
Table 1: Select characteristics of cardiac surgical patients by statin initiation status within surgery type
Characteristic All patients CABG patients Non-CABG patients
Non-users
(n = 2597)
Statin initiators
(n = 1107)
Non-users
(n = 979)
Statin initiators
(n = 950)
Non-users
(n = 1618)
Statin initiators
(n = 157)
Female (%) 32.5 20.8 23.8 18.1 37.8 36.9
Age, mean (SD) 64.6 (15.3) 67.5 (9.8) 68.8 (10.4) 67.1 (9.6) 62.1 (17.2) 69.9 (10.4)
Body mass index, mean (SD) 26.4 (4.7) 26.8 (4.1) 27.0 (4.4) 27.0 (4.1) 25.9 (4.9) 26.1 (4.2)
Glomerular filtration rate, mean (SD) 77.7 (23.5) 77.9 (18.5) 74.1 (21.2) 78.9 (18.2) 80.0 (24.4) 73.0 (18.7)
Diabetes (%) 9.9 8.4 17.5 8.8 5.3 5.7
Charlson Comorbidity Index
Low (0) (%) 48.8 46.3 44.3 46.0 51.5 47.8
Medium (1–2) (%) 38.2 43.2 37.9 43.7 38.4 40.1
High (>2) (%) 13.0 10.6 17.8 10.3 10.1 12.1
Prior cardiac surgery (%) 28.3 42.2 43.3 45.6 19.2 21.7
Prior myocardial infarction (%) 8.5 27.4 16.3 30.0 3.8 11.5
ACE inhibitor use (%) 20.1 30.5 20.6 30.4 19.8 31.2
Aprotinin use (%) 10.1 1.6 2.9 0.6 10.1 7.0
Calcium-channel blocker use (%) 16.1 24.3 21.5 25.0 12.9 20.4
β-Blocker use (%) 33.7 76.4 36.7 80.5 31.9 51.6
NSAID use (%) 13.3 11.7 13.6 11.5 13.1 12.7
EuroSCORE
Low risk (%) 16.9 32.0 19.8 35.6 15.2 10.2
Medium risk (%) 33.4 37.3 33.09 38.5 33.6 29.9
High risk (%) 49.7 30.7 47.09 25.9 51.2 59.9
CABG: coronary artery bypass graft; SD: standard deviation; GFR: glomerular filtration rate; ACE: angiotensin-converting enzyme; NSAID: non-steroidal
anti-inflammatory drug; EuroSCORE I: European System for Cardiac Operative Risk Evaluation I.
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in non-CABG patients) than non-CABG patients. However, non-
CABG patients tended to have higher EuroSCOREs, indicating
higher risk surgical procedures.
Some covariate information was missing for characteristics col-
lected at the time of surgery: smoking status, BMI, peripheral arter-
ial disease, unstable angina, left ventricular ejection fraction,
pulmonary hypertension and previous percutaneous coronary
intervention. Some variables appeared to be missing more fre-
quently in the non-users than in statin initiators, including: smoking
status, BMI and previous percutaneous coronary intervention.
Overall, 343 (13.2%) of the non-users and 70 (6.3%) of the statin
initiators were excluded from the multivariable and PS analyses due
to missing covariate information. The distribution of missingness
was less pronounced by surgery type: 189 (9.8%) of CABG patients
and 224 (12.6%) of non-CABG patients were excluded for missing
information.
When comparing characteristics by statin treatment, treated
and untreated groups appear similar in many regards, but statin
initiators had more prior cardiovascular interventions, myocardial
infarctions and medication use. However, there was more CKD
stage 3+ among the non-users than the statin initiators. The plots
of the PS distributions by treatment group (Fig. 2) show separation
of the curves, suggesting underlying differences in measured con-
founders between treatment groups.
We observed differences in statin initiation between the CABG
and non-CABG patients (see Table 1); 49% of statin-naïve CABG
patients initiated a statin in the 100 days prior to surgery, while only
9% of non-CABG patients did. Among CABG patients, statin initia-
tors tended to have slightly better-managed cardiovascular disease,
as evidenced by fewer comorbidities, more cardiovascular medica-
tion and higher ejection fraction. However, there was a much larger
prevalence of former myocardial infarction among statin initiators
than non-users, more CKD stage 3+ and more blood transfusion
required. CABG patients on a statin also had lower EuroSCOREs.
Among non-CABG patients, statin initiators were older and had
more comorbidities, lower ejection fraction, more medication use,
more recent cardiovascular events and a higher EuroSCORE, indi-
cating more complex surgeries and CAD. PS overlap was better in
the surgical subgroups (see Supplementary Fig. 1), indicating more
comparability between statin initiators and non-users within surgi-
cal subtypes, although differences still do remain.
Post-surgical AKI was frequent; AKI occurred following 25% of
CABG and 28% of non-CABG surgeries. The majority of AKI events
(77%) were mild, Stage 1; however, non-CABG patients tended to
experience more severe AKI events.
Post-surgical AKI occurred in 21% of the non-users and 29% of
the statin initiators. Among all patients, the crude RR for statin initi-
ation on post-surgical AKI was 0.74 (95% CI: 0.65, 0.84). Upon ad-
justment, the effect was attenuated to RR = 0.86 (95% CI: 0.75, 0.99),
and upon SMR weighting, remained very similar, RR = 0.82 (95% CI:
0.69, 0.99), suggesting a protective effect of presurgical statin initi-
ation on post-surgical AKI (see Table 2). Upon SMR weighting, the
Figure 2: Propensity score overlap of presurgical statin initiators and non-users: (A) original sample; (B) standardized mortality ratio weighted.
Table 2: Effect measure estimates of presurgical statin initiation on post-surgical acute kidney injury
Surgery Treatment N Events % Crude Adjusteda SMRW weighteda
RR (95% CI) RR (95% CI) RR (95% CI)
All Non-user 2,597 749 28.8 – – – – – –
Statin initiator 1,107 235 21.2 0.74 (0.65, 0.84) 0.86 (0.74, 0.98) 0.82 (0.69, 0.98)
CABG Non-user 979 288 29.4 – – – – – –
Statin initiator 950 192 20.2 0.69 (0.59, 0.81) 0.88 (0.74, 1.05) 0.87 (0.68, 1.12)
Non-CABG Non-user 1,618 461 28.5 – – – – – –
Statin initiator 157 43 27.4 0.96 (0.74, 1.25) 0.87 (0.68, 1.11) 0.88 (0.68, 1.16)
SMRW: standardized mortality ratio weight; RR: risk ratio; CI: confidence interval; CABG: coronary artery bypass graft.
aVariable included in adjusted and propensity score models include: age; sex; body mass index category; surgical centre; chronic kidney disease; aprotinin use;
blood transfusion amount; diabetes; peripheral arterial disease; unstable angina; left ventricular dysfunction; pulmonary hypertension; prior percutaneous
coronary intervention; prior cardiac surgery; ACE inhibitor use; angiotensin receptor blocker use; diuretic use; calcium-channel blocker use; β-blocker use;
non-steroidal anti-inflammatory drug use; prior myocardial infarction; prior heart failure; prior arrhythmias; prior atrial fibrillation; prior stroke.
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PS distribution curves were much more similar, suggesting ex-
changeability between the treatment groups in the resulting pseu-
dopopulation (see Fig. 2 and Supplementary Table 2).
When stratified by surgery type, the crude RR for statin initi-
ation in CABG surgeries was protective, RR = 0.69 (95% CI: 0.59,
0.81), while the crude estimate among non-CABG surgeries was
null, RR = 0.96 (95% CI: 0.74, 1.25). Upon adjustment, the effect
measure estimates were similarly protective to the effect measure
in the overall population: CABG patients, RR = 0.88 (95% CI: 0.74,
1.05); non-CABG surgeries, RR = 0.87 (95% CI: 0.68, 1.11).
In sensitivity analyses with more narrowly defined surgical popu-
lations, surgical severity varied greatly between surgical types as
indicated by varying EuroSCORE. Aortic surgeries, CABG + aortic
valve surgeries, and complex surgeries had the highest mean
EuroSCOREs and highest rates of post-surgical AKI. Simple CABG
procedures had the lowest EuroSCOREs. Sample sizes were much
smaller in some cases, resulting in imprecise effect measure esti-
mates (or an inability to calculate estimates), although among the
subgroups which could be estimated, subgroup effects were
consistent with the overall effects (see Supplementary Table 3).
However, an exception was CABG + aortic valve procedures, one of
the highest risk subtypes, where the adjusted RR = 1.18 (95% CI:
0.84, 1.66) suggested no protective effect. Additionally, in sensitivity
analyses stratified by sex, CKD status (GFR <60 vs GFR ≥60) and
presence of a former myocardial infarction, all estimates were con-
sistent with the overall estimate, except in GFR <60, which showed
no protective effect (see Supplementary Table 4).
In sensitivity analyses where cubic splines were employed for
continuous covariates, the effect estimate was identical to the
primary analysis in the overall population. There was no difference
in estimates between the two surgical centres.
DISCUSSION
We observed reduced AKI risk associated with statin initiation prior
to cardiac surgery in those previously unexposed to statins. We
observed a high rate of post-surgical AKI, and the majority of these
events were AKIN stage 1, which may not be clinically recognized
or diagnosed, and thus would not have been identified in popula-
tion studies relying on administrative claims databases. However,
using sCr-based AKIN criteria allowed us to identify mild AKI
events which have been demonstrated to have long-term negative
effects [2].
Multiple beneficial effects independent of lipid-lowering have
been attributed to statins, including reducing inflammation [18],
improving fibroproliferative responses [19], stabilizing atheroscler-
otic plaques [20], improving left ventricular ejection fraction [18]
and inhibiting the mevalonate–isoprenoid pathway which lessens
ischaemia–reperfusion injury [21], all of which may protect one
from surgically induced AKI. The protective effect was less pro-
nounced in the most complex surgical types and the highest risk
patients, but our study demonstrated that even short courses of
presurgical treatment yield modest protection against AKI.
This protective effect was similar when investigating the full sur-
gical population, or when evaluating CABG and non-CABG surger-
ies separately. CABG and non-CABG surgeries had similar adjusted
effect estimates; however, due to differing patient populations, the
crude risk ratios and confounding were in opposite directions. In
CABG patients, statins seemed to indicate better CVD manage-
ment and subsequently showed a very protective crude RR, while
in non-CABG patients, statin initiation seems to be a marker of
CAD in addition to the structural cardiac problem, resulting in a
null crude RR. However, upon adjustment, both groups yielded
similar, modestly protective effect estimates. Statins tend to be
used primarily as secondary prevention in Denmark [22]; thus
their use is more closely associated with progressed CAD than in
the USA, where many previous studies [4, 5] of presurgical statin
use were performed.
Our estimate generally agrees with findings from previous
studies, including studies of prevalent statin use not considering
the duration of use [4], a study looking at presurgical new use [23]
and a study considering continuing versus discontinuing a statin
prior to surgery [24].
The current study design focused on statin initiation prior to
surgery rather than long-term prior use, seeking to answer the
clinically relevant question of whether a previously statin-naïve
patient should initiate a statin when the need for cardiac surgery is
determined, and our results suggest that even relatively short-
term presurgical statin use may be beneficial for renal function. By
employing a new-user design [25], we reduced the healthy-user
effect [10] by avoiding comparing long-term users with non-users
where better adherence, healthy lifestyle, other behavioural dif-
ferences and failure to observe early adverse events lead to exag-
gerated or spurious estimates of benefit. A previous study using
the new-user design attenuated these biases [23] and demon-
strated a similar protective effect, yet it employed administrative
claims and lacked detailed surgical factors, baseline renal function
and a biomarker-based definition of AKI. Another recent study
accounted for treatment duration by only considering continu-
ation versus discontinuation of pre-existing statin use prior to
surgery and found that continuing a statin was associated with
reduced levels of kidney injury biomarkers [24].
As with all non-interventional studies, there are potential limita-
tions of this analysis. We relied on recorded statin dispensing, and
there may be misclassification of true statin exposure. However, all
medication studies are subject to non-compliance, reflecting the
reality of treatment options available to physicians where therapies
can be prescribed but rarely can be enforced. Statin initiation may
be associated with factors leading to better clinical outcomes, such
as better patient compliance, a more engaged healthcare provider
or better healthcare quality. Some missing covariate data did
appear to be somewhat associated with statin initiation, perhaps in-
dicating better presurgical assessment or care. If patients with
missing data had systematically different outcomes, this may have
biased our result. However, universal healthcare access in Denmark
should reduce confounding by access to care, and all surgeries
were performed in two tertiary care, academic hospitals, reducing
differential AKI detection or presurgical care by statin status.
Additionally, unmeasured confounding may remain in spite of re-
striction and adjustment; in CABG patients, statin users had slightly
less renal impairment (although non-CABG patients had slightly
more), and although we adjusted for this and other confounders,
statin use may continue to be associated with unmeasured lifestyle
and behavioural factors associated with better outcomes. However,
in other respects, statin users appear to be less healthy (e.g. more
smoking, obesity), particularly among non-CABG patients. CABG
and non-CABG patients had different confounding structures, and
yet the adjusted effect estimates are very similar.
When investigating specific surgery types in sensitivity analyses,
we observed estimates consistent with the overall and the CABG,
non-CABG subgroup effects for most groups. However, a null
effect was observed in patients undergoing a combined CABG and
aortic valve procedure and in those with pre-existing renal
A
D
U
LT
C
A
R
D
IA
C
J.B. Layton et al. / European Journal of Cardio-Thoracic Surgery 999
D
ow
nloaded from
 https://academ
ic.oup.com
/ejcts/article-abstract/49/3/995/2465464 by Bernetta Evans user on 13 August 2019
dysfunction. These are higher risk, more invasive and longer pro-
cedures and patients already at a high risk of AKI, and it is possible
that any protective effect of statin use may be more pronounced
in lower risk surgeries with milder insult to the kidneys.
This study has many strengths resulting from the rigorous study
design and rich clinical data. Danish registries provide detailed surgi-
cal characteristics and pharmacy dispensing information for patients.
We utilized longitudinally collected sCr measures to determine AKI
status, and detailed clinical information about the surgical proce-
dures allowed us to adjust for surgical complexity and baseline renal
function. We evaluated different surgical types with differing aetiolo-
gies and AKI risk profiles. We had comprehensive patient medica-
tion histories, allowing us to exclude long-term statin users, reducing
selection bias. Additionally, we restricted the study to a homoge-
neous patient population of planned, non-emergency surgeries.
In conclusion, initiation of a statin prior to cardiac surgery was
associated with a reduced risk of post-surgical AKI in those previ-
ously unexposed to statins. AKI is common after cardiac surgery,
and measures to reduce AKI have the potential to reduce hospital
length of stay, and long-term renal and cardiovascular events.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at EJCTS online.
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